| Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery J Kao, K Salari, M Bocanegra, YL Choi, L Girard, J Gandhi, KA Kwei, ... PloS one 4 (7), e6146, 2009 | 920 | 2009 |
| Identification of recurrent SMO and BRAF mutations in ameloblastomas RT Sweeney, AC McClary, BR Myers, J Biscocho, L Neahring, KA Kwei, ... Nature genetics 46 (7), 722-725, 2014 | 349 | 2014 |
| Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer KA Kwei, YH Kim, L Girard, J Kao, M Pacyna-Gengelbach, K Salari, J Lee, ... Oncogene 27 (25), 3635-3640, 2008 | 240 | 2008 |
| Genomic instability in breast cancer: pathogenesis and clinical implications KA Kwei, Y Kung, K Salari, IN Holcomb, JR Pollack Molecular oncology 4 (3), 255-266, 2010 | 197 | 2010 |
| Genomic Profiling Identifies GATA6 as a Candidate Oncogene Amplified in Pancreatobiliary Cancer KA Kwei, MD Bashyam, J Kao, R Ratheesh, EC Reddy, YH Kim, ... PLoS genetics 4 (5), e1000081, 2008 | 121 | 2008 |
| Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression A Gupta, B Butts, KA Kwei, K Dvorakova, SP Stratton, MM Briehl, ... Cancer letters 173 (2), 115-125, 2001 | 91 | 2001 |
| Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer YH Kim, KA Kwei, L Girard, K Salari, J Kao, M Pacyna-Gengelbach, ... Oncogene 29 (10), 1421-1430, 2010 | 87 | 2010 |
| Transcriptional repression of catalase in mouse skin tumor progression KA Kwei, JS Finch, EJ Thompson, GT Bowden Neoplasia 6 (5), 440-448, 2004 | 80 | 2004 |
| Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis A Noy, S de Vos, M Coleman, P Martin, CR Flowers, C Thieblemont, ... Blood Advances 4 (22), 5773-5784, 2020 | 78 | 2020 |
| First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III … C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz, L Larratt, M Simkovic, ... Haematologica 107 (9), 2108, 2022 | 76 | 2022 |
| SMURF1 amplification promotes invasiveness in pancreatic cancer KA Kwei, AH Shain, R Bair, K Montgomery, CA Karikari, M van de Rijn, ... PloS one 6 (8), e23924, 2011 | 72 | 2011 |
| CAMK1D amplification implicated in epithelial–mesenchymal transition in basal-like breast cancer A Bergamaschi, YH Kim, KA Kwei, Y La Choi, M Bocanegra, A Langerød, ... Molecular oncology 2 (4), 327-339, 2008 | 65 | 2008 |
| Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma AF Herrera, A Goy, A Mehta, R Ramchandren, JM Pagel, J Svoboda, ... American journal of hematology 95 (1), 18-27, 2020 | 55 | 2020 |
| Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection KA Kwei, JB Baker, RJ Pelham Public Library of Science 7 (9), e46518, 2012 | 54 | 2012 |
| Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma N Barasch, X Gong, KA Kwei, S Varma, J Biscocho, K Qu, N Xiao, ... PLoS One 12 (2), e0171265, 2017 | 48 | 2017 |
| Catalase reverses tumorigenicity in a malignant cell line by an epidermal growth factor receptor pathway JS Finch, ME Tome, KA Kwei, GT Bowden Free Radical Biology and Medicine 40 (5), 863-875, 2006 | 39 | 2006 |
| The role of Rac1 in maintaining malignant phenotype of mouse skin tumor cells KA Kwei, JS Finch, J Ranger-Moore, GT Bowden Cancer letters 231 (2), 326-338, 2006 | 36 | 2006 |
| Elevated basal reactive oxygen species and phospho‐Akt in murine keratinocytes resistant to ultraviolet B–induced apoptosis BD Butts, KA Kwei, GT Bowden, MM Briehl Molecular Carcinogenesis: Published in cooperation with the University of …, 2003 | 28 | 2003 |
| Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer N Clarke, J Biscocho, KA Kwei, JM Davidson, S Sridhar, X Gong, ... PLoS One 10 (11), e0142061, 2015 | 20 | 2015 |
| Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features … JA Burger, T Robak, F Demirkan, O Bairey, C Moreno, D Simpson, ... Leukemia & Lymphoma 63 (6), 1375-1386, 2022 | 8 | 2022 |
